Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypercholesterolemia

In brief

To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.

Key facts

Study ID

NCT01926782

Run by

Regeneron Pharmaceuticals

People needed

803

Starts

2013-09-01

Expected to finish

2015-04-01

Last updated by the study team

2017-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women > age 18 or legal age of majority with elevated LDL-C
• Patients not having adequate control of their hypercholesterolemia based on their individual level of CVD risk
• Willing and able to comply with clinic visits and study-related procedures
• Provided signed informed consent

You may not qualify if…

• Recent (within 3 months prior to the screening visit) myocardial infarction, unstable angina leading to hospitalization, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease
• Known history of positive test for human immunodeficiency virus (HIV)
• Any clinically significant abnormality identified at the time of screening that in the judgment of the investigator or any sub-investigator would preclude safe completion of the study or constrain assessment of endpoints, such as major systemic diseases or participants with short life expectancy.
• Participants considered by the investigator or any sub-investigator to be inappropriate for this study (e.g, geographic or social), actual or anticipated, that the investigator felt would restrict or limit the participant's participation for the duration of the study.
• Certain laboratory findings obtained during the screening period
• The information listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial and not all inclusion/ exclusion criteria are listed.

Where it is running

• Study site — Goodyear, Arizona, United States
• Study site — Carmichael, California, United States
• Study site — Fresno, California, United States
• Study site — West Hills, California, United States
• Study site — Wildomar, California, United States
• Study site — Colorado Springs, Colorado, United States
• Study site — Golden, Colorado, United States
• Study site — Boynton Beach, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Safety Harbor, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Boise, Idaho, United States
• Study site — Meridian, Idaho, United States
• Study site — Chicago, Illinois, United States
• Study site — Gurnee, Illinois, United States
• Study site — Evansville, Indiana, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Iowa City, Iowa, United States
• Study site — Kansas City, Kansas, United States
• Study site — Louisville, Kentucky, United States
• Study site — Monroe, Louisiana, United States
• Study site — Auburn, Maine, United States
• Study site — Methuen, Massachusetts, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Chandler, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.